ZURICH – Novartis AG (NVS) said Thursday the development program of an experimental drug for the treatment of Hepatitis C has been placed on hold by U.S. regulators after the death of a patient, which may be linked the drug. A small number of patients treated with the DEB025 drug or alisporivir developed pancreatitis, which is believed to be a contributing factor to the death, Novartis said.
